







**Single Genes can modify behavior: Worms;  
Flies; Mice; Humans**



**Social Behavior in *C. elegans*.**


- Mutation in a neuropeptide-Y-like protein; the NPR-1 receptor. In mammals, important for “feeding”.
- Clumping is controlled by an unknown neuropeptide acting through the receptor.
- Secretion of the neuropeptide is probably regulated by food.
- **Proposed Model:**

**Dispersing strains have a repellant response (mediated by NPR-1 receptor) that masks the attractant response.**



### The Sleep Disorder Canine Narcolepsy is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene.

*L. Lin et al., Cell 98 365 1999*



**Narcolepsy in orexin Knockout Mice: Molecular Genetics of Sleep Regulation.**  
*RM Chemelli et al., Cell 98, 437 1999*

**Narcolepsy: debilitating, neurological disorder characterized by:**

1. Sleep attacks
2. Episodic loss of muscle tone (cataplexy)
3. Hypnagogic hallucinations
4. Abnormal sleep-wake cycle

### The Sleep Disorder Canine Narcolepsy is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene.

*L. Lin et al., Cell 98 365 1999*

### Reduced Number of Hypocretin Neurons in Human Narcolepsy

*TC Thannickal et al., Neuron 27; 469 2000*

**Distribution of Cells in Perifornical and Dorsomedial Hypothalamic Regions of Normal and Narcoleptic Humans**

- On average, narcoleptics have 7% of the *Hert* cells seen in normals
- C and D – low power covering regions shown in grey at top
- E and G – normal subjects
- F and H – narcoleptic subjects

• *Most human narcolepsy is NOT familial; is discordant in identical twins; and NOT linked to mutations in hypocretin.*

### Narcolepsy: summary

#### Hypothetical Effect of Blunted *Hcrt* Activation:

1. Monoaminergic Nuclei of the Brainstem: induce cataplexy.
2. Cholinergic Brainstem and Basal Forebrain: cause sleepiness associated with narcolepsy.
3. Dense *Hcrt* Projections to the Suprachiasmatic Nucleus: reduced amplitude of circadian sleep rhythms, and thereby increased sleepiness during the day and interrupted sleep at night.

### The Essential Role of Hippocampal CA1 NMDA Receptor-Dependent Synaptic Plasticity in Spatial Memory


*JZ Tsien, PT Huerta, and S. Tonegawa, Cell 87 1327 1996.*

#### Summary of Hippocampal Studies since 1957:

1. Required for certain kinds of memory; spatial in rodents; facts and faces in humans.
  2. Rodent hippocampal neurons are "place cells"; 'fire' when animal moves into marked area.
  3. Hippocampal synapses exhibit LTP (paradigm for synaptic plasticity).
- *Tsien et al.*: use cre/loxP recombination system to delete NMDA receptor function only in CA1 subregion.
  - **THUS**: By effecting CA1-specific NMDA receptor inactivation, the studies relate synaptic plasticity to neuronal activity (place fields) and to spatial learning.


### The Essential Role of Hippocampal CA1 NMDA Receptor-Dependent Synaptic Plasticity in Spatial Memory

*JZ Tsien, PT Huerta, and S. Tonegawa, Cell 87 1327 1996.*



### The Essential Role of Hippocampal CA1 NMDA Receptor-Dependent Synaptic Plasticity in Spatial Memory

*JZ Tsien, PT Huerta, and S. Tonegawa, Cell 87 1327 1996.*



### The Essential Role of Hippocampal CA1 NMDA Receptor-Dependent Synaptic Plasticity in Spatial Memory

*JZ Tsien, PT Huerta, and S. Tonegawa, Cell 87 1327 1996.*





Table 3-1 Neurological Diseases Involving Trinucleotide Repeats<sup>1</sup>

Disease	Repeat	Repeat length <sup>2</sup>	Gene product
X-linked spinal and bulbar muscular atrophy	CAG	Normal: 11-34 Disease: 40-62	Androgen receptor
Fragile X mental retardation <sup>3</sup>	CGG	Normal: 6 to ~50 Premutation: 52-200 Disease: 200 to >1000	FMR-1 protein
Myotonic dystrophy <sup>3</sup>	CTC	Normal: 5-30 Premutation: 42-180 Disease: 200 to >1000	Myotonin protein kinase
Huntington disease	CAG	Normal: 11-34 Disease: 37-121	Huntingtin
Spinocerebellar ataxia type 1	CAG	Normal: 19-36 Disease: 43-81	Ataxin-1
FRAXE mental retardation <sup>3</sup>	GCC	Normal: 6-25 Disease: >200	?
Dentatorubral-pallidolysian atrophy	CAG	Normal: 7-23 Disease: 49-75	?



**Most Human Behaviors are Likely to be Genetically Complex: i.e., result from the complex interaction of multiple genes together with non-genetic (environment; stochastic) factors.**

**Genetics of Autism**

---

**Twin Studies**

- **Monozygotic twins are about 78% concordant for autism and spectrum disorders.**
- **Dizygotic twins are about 17% concordant.**

**Recurrence Risk**



- **Approximately 3% of affected probands have an affected sibling with autism (15% for autism + spectrum).**
- **Relative risk**
- **Recurrence risk/prevalence**
- **50-100 fold increase risk to first-degree relatives compared to general population.**


**Genetics of Autism**

---

- **Very high:** MZ:DZ twin ratio
- **Relatively low:** 'sibling-risk' (recurrence risk)
- **Very high:** 'relative risk'

**Interpretation:** Autism is strongly influenced by genetic factors; multiple genes contribute; each single gene effect is probably small; epistatic interactions are likely.





**Heritability of Psychiatric Disorders**  
*Degree to which heritable (genetic) factors influence expression of disease or trait*

Schizophrenia	50-60%
Bipolar Disorder	60-70%
Panic Disorder	30-40%
Obsessive-Compulsive Disorder	60-80% (small studies)
ADHD	60%
Reading Disability	50%
Autism (+ spectrum)	90%
Personality	40-60%
Nicotine Addiction	50% for initiation, 70% for 10 yr. persistence

**Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking**

Richard P. Ebstein<sup>1,3</sup>, Olga Novick<sup>2</sup>, Roberto Umansky<sup>2</sup>, Beatrice Priel<sup>2</sup>, Yamima Osher<sup>2</sup>, Darren Blaine<sup>1</sup>, Estelle R. Bennett<sup>1</sup>, Lubov Nemanov<sup>1</sup>, Miri Katz<sup>1</sup> & Robert H. Belmaker<sup>2</sup>

**Alzheimer's Disease is currently the best example of a complex disease with known genetic etiology.**

**Alzheimer's Disease**

1. Degenerating disorder of the CNS leading to a progressive decline in memory, reasoning, judgement and orientation
2. Affects 2-5 million people in the U.S.A.
3. Fourth leading cause of death in the U.S.A.
4. Patients generally live 5-10 years after onset and often require institutionalized care; 25 billion dollars / year in U.S.A.
5. By the early 21st century, due to the increasing rate of life-expectancy, approximately 1 in every 5 people in the U.S.A. will suffer some form of dementia.

**Etiology of Alzheimer's Disease**



1. Classically: considered non-genetic
2. Affects: 1/10 over age of 65, 1/3 over age of 85
3. Epidemiology Studies: increased risk among relatives of patients with A.D.
4. Pedigrees: Autosomal dominant form of inheritance usually characterized by an early age of onset (Familial Alzheimer's Disease).

**TABLE 1. Genetic susceptibility loci in Alzheimer disease**

Chromosome	Gene	Onset	Proportion of cases (%)	Comments
1	Presenilin II	Early	<1	Mainly Volga German
14	Presenilin I	Early	<5	Autosomal dominant
19	APOE	Both	40-50	Dose effect on risk
21	APP	Early	<<1	Autosomal dominant
?	?	Late	=50	Unknown number of genes

## Apolipoprotein E (APOE) and AD

- APOE is a major serum lipoprotein involved in cholesterol metabolism.
- Synthesized in the brain by astrocytes
- In the brain, APOE is thought to be involved in mobilization and redistribution of cholesterol and phospholipid during membrane remodeling associated with plasticity of synapses.



**FIG. 1.** Age of onset for subjects in late-onset Alzheimer disease families with zero, one, and two APOE4 alleles. Each curve is labeled with the number of inherited APOE4 alleles. An asterisk indicates multiple diagnoses within a short interval. Onset curves were estimated by Kaplan-Meier product limit distributions (SAS Institute Inc.). For example, at age 75, an estimated 24% of subjects without APOE4 were diagnosed with AD compared to 64% of subjects with one APOE4 allele and 89% of subjects with two APOE4 alleles. Note that there is a dose-dependent effect of each APOE4 allele. [Reprinted from Corder et al. (5), © 1988 by the AAAS.]

### Apolipoprotein E - e4

- e4/e4 AD patients show markedly more APP deposition in plaques relative to non-e4 AD patients
- ApoE e4 binds BA4 peptide with greater avidity than e3 isoform.
- ApoE e4 shows significant allelic association in familial and sporadic late onset AD, and in familial early onset AD.
  - e4 heterozygote is 3X more likely to be affected than e2/e3 or e3/e3
  - e4 homozygote is 8X more likely to be affected

**Conclusion:** ApoE e4 gene dose is a major risk factor for late (and possibly early) onset AD. Inheritance of two e4 alleles is not necessary and probably not sufficient to cause AD.